BACKGROUND: In severe @entity1663 ( @entity1663 ), spontaneous recovery is unlikely, and treatment is not standardized. OBJECTIVE: To evaluate the efficacy and safety of @entity1499 ( @entity6822 ) used alone or combined with low- to moderate-dose oral @entity288 (OC) for treating severe @entity1663 (totalis, universalis and severe multifocal). METHODS: Retrospective monocentric study of all consecutive @entity1 receiving this treatment between 2006 and 2012. Efficacy was defined as achieving a total regrowth of terminal hair. RESULTS: 26 @entity1 were included (17 with @entity1663 universalis or totalis and 9 with severe multifocal @entity1663 ). Total regrowth was noted in 15/26 @entity1 . After 3 months of treatment, hair regrowth >80% was associated with further complete regrowth, and hair regrowth <30% was associated with later treatment failure (p = 0.0014). When treatment was tapered, 11/15 @entity1 with initial complete efficacy experienced @entity1663 relapse. CONCLUSION: @entity6822 combined with low- to moderate-dose OC may be an efficient and well-tolerated treatment for severe @entity1663 . However, long-term maintenance treatment is usually required.

Efficacy and Safety of XXXX Combined with Low- to Moderate-Dose Corticosteroids for Severe Alopecia Areata.

@entity1 :: ('9606', 'Species') :: ['patients'] @entity6822 :: ('D008727', 'Chemical') :: ['MTX'] @entity1499 :: ('MESH:D008727', 'Chemical') :: ['methotrexate'] @entity1663 :: ('MESH:D000506', 'Disease') :: ['AA', 'alopecia areata'] @entity288 :: ('MESH:D000305', 'Chemical') :: ['corticosteroids']
@entity1499 :: (MESH:D008727,Chemical) :: ['Methotrexate']
